期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
扶正解毒微粉与扶正解毒散体外抗IBDV药效对比试验
1
作者 张传津 陈炳见 《中国兽医杂志》 CAS 北大核心 2018年第12期60-61,共2页
将100℃浸泡制备的扶正解毒微粉和扶正解毒散溶液分别用生理盐水稀释成5个浓度,每个浓度经绒毛尿囊膜接种10~12月龄SPF鸡胚6枚,每胚0.2 mL,测定其对鸡胚的安全浓度;然后将由扶正解毒微粉和扶正解毒散制备的溶液在安全浓度下倍比稀释至... 将100℃浸泡制备的扶正解毒微粉和扶正解毒散溶液分别用生理盐水稀释成5个浓度,每个浓度经绒毛尿囊膜接种10~12月龄SPF鸡胚6枚,每胚0.2 mL,测定其对鸡胚的安全浓度;然后将由扶正解毒微粉和扶正解毒散制备的溶液在安全浓度下倍比稀释至500、250、125μg mL-13个浓度,分别与传染性法氏囊病毒(IBDV)在37℃共同培育1 h后,每个浓度中药和法氏囊病毒混合液经绒毛尿囊膜接种10~12月龄SPF鸡胚6枚,每胚0.2 mL,测定其ELD50,计算各病毒滴度。结果表明,在所选浓度范围内扶正解毒微粉和扶正解毒散制备溶液都可以降低病毒滴度值,且高浓度效果优于低浓度;同浓度扶正解毒微粉效果优于扶正解毒散。 展开更多
关键词 扶正解毒散 超微粉 抵抗病毒感染 鸡传染性腔上囊病毒
下载PDF
Prevalence and evolution of drug resistance HIV-1 variants in Henan, China 被引量:34
2
作者 Jing Yun LI Han Ping LI +9 位作者 Lin LI Hong LI Zhe WANG Kun YANG Zuo Yi BAO Dao Min ZHUANG Si Yang LIU Yong Jian LIU Hui XING Yi Ming SHAO 《Cell Research》 SCIE CAS CSCD 2005年第11期843-849,共7页
To understand the prevalence and evolution of drug resistant HIV strains in Henan China after the implementation of free antiretroviral therapy for AIDS patients. 45 drug naive AIDS patients, 118 AIDS patients who rec... To understand the prevalence and evolution of drug resistant HIV strains in Henan China after the implementation of free antiretroviral therapy for AIDS patients. 45 drug naive AIDS patients, 118 AIDS patients who received three months antiretroviral therapy and 124 AIDS patients who received six months antiretroviral treatment were recruited in the southern part of Henan province. Information on general condition, antiretroviral medicines, adherence and clinical syndromes were collected by face to face interview. Meanwhile, 14ml EDTA anticoagulant blood was drawn. CD4/CD8 T cell count, viral load and genotypic drug resistance were tested. The rates of clinical improvement were 55.1% and 50.8% respectively three months and six months after antiretroviral therapy. The mean CD4 cell count after antiretroviral therapy was significantly higher than in drug naive patients. The prevalence rate of drug resistant HIV strains were 13.9%, 45.4% and 62.7% in drug naive patients, three month treatment patients and six month treatment patients, respectively. The number of resistance mutation codons and the frequency of mutations increased significantly with continued antiretroviral therapy. The mutation sites were primarily at the 103, 106 and 215 codons in the three-month treatment group and they increased to 15 codon mutations in the six-month treatment group. From this result, the evolution of drug resistant strains was inferred to begin with the high level NNRTI resistant strain, and then develop low level resistant strains to NRTIs. The HIV strains with high level resistance to NVP and low level resistance to AZT and DDI were highly prevalent because of the AZT+DDI+NVP combination therapy. These HIV strains were also cross resistant to DLV, EFV, DDC and D4T. Poor adherence to therapy was believed to be the main reason for the emergence and prevalence of drug resistant HIV strains. The prevalence of drug resistant HIV strains was increased with the continuation of antiretroviral therapy in the southern part of Henan province. Measures, that could promote high level adherence, provide new drugs and change ART regimens in failing patients, should be implemented as soon as possible. 展开更多
关键词 AIDS drug resistance ADHERENCE antiretroviral therapy
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部